{"id":411839,"date":"2025-12-11T00:30:00","date_gmt":"2025-12-10T23:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/nouvelles-perspectives-dans-le-traitement-de-premiere-ligne\/"},"modified":"2025-12-10T21:16:04","modified_gmt":"2025-12-10T20:16:04","slug":"nouvelles-perspectives-dans-le-traitement-de-premiere-ligne","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/nouvelles-perspectives-dans-le-traitement-de-premiere-ligne\/","title":{"rendered":"Nouvelles perspectives dans le traitement de premi\u00e8re ligne"},"content":{"rendered":"\n

Dans le cadre de la Conf\u00e9rence mondiale<\/em> de l’IASLC sur le cancer du poumon<\/em> (WCLC 2025) qui s’est tenue cette ann\u00e9e \u00e0 Barcelone, un poster de l’\u00e9tude FLAURA2 a pr\u00e9sent\u00e9 de nouvelles donn\u00e9es sur le traitement combin\u00e9 par osimertinib en premi\u00e8re ligne du cancer du poumon non \u00e0 petites cellules (NSCLC) mut\u00e9 EGFR (EGFRm). <\/em>L’\u00e9tude a montr\u00e9 que <\/em>osimertinib associ\u00e9 \u00e0 une chimioth\u00e9rapie \u00e0 base de pemetrexed avec du cisplatine ou du carboplatine r\u00e9duisait le risque de mortalit\u00e9 de 23% par rapport \u00e0 la monoth\u00e9rapie, avec des effets secondaires en principe contr\u00f4lables. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Dans le cadre de la Conf\u00e9rence mondiale de l’IASLC sur le cancer du poumon (WCLC 2025) qui s’est tenue cette ann\u00e9e \u00e0 Barcelone, un poster de l’\u00e9tude FLAURA2 a pr\u00e9sent\u00e9……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":411841,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cancer du poumon avec mutation de l'EGFR","footnotes":"[{\"id\":\"e88b0f85-a52c-4cc0-be2c-2e37b16bcaa3\",\"content\":\"www.swissmedic.ch\\\/swissmedic\\\/de\\\/home\\\/humanarzneimittel\\\/authorisations\\\/new-medicines.html<\\\/a>
www.ema.europa.eu\\\/en\\\/documents\\\/overview\\\/tagrisso-epar-medicine-overview_en.pdf<\\\/a>\"}]"},"category":[11549,11527,11389,11477,11535],"tags":[57902,83874,86059,86057,86065,86058,86135],"powerkit_post_featured":[],"class_list":["post-411839","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-etudes","category-oncologie","category-pneumologie-fr","category-rapports-de-congres","tag-carboplatine","tag-cisplatine","tag-egfrm-nsclc","tag-flaura-2","tag-flaura2","tag-pemetrexed","tag-therapie-combinee-a-losimertinib","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-11 21:45:56","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":411894,"slug":"nuove-prospettive-nella-terapia-di-prima-linea","post_title":"Nuove prospettive nella terapia di prima linea","href":"https:\/\/medizinonline.com\/it\/nuove-prospettive-nella-terapia-di-prima-linea\/"},"pt_PT":{"locale":"pt_PT","id":411850,"slug":"novas-perspectivas-na-terapia-de-primeira-linha","post_title":"Novas perspectivas na terapia de primeira linha","href":"https:\/\/medizinonline.com\/pt-pt\/novas-perspectivas-na-terapia-de-primeira-linha\/"},"es_ES":{"locale":"es_ES","id":411846,"slug":"nuevas-perspectivas-en-la-terapia-de-primera-linea","post_title":"Nuevas perspectivas en la terapia de primera l\u00ednea","href":"https:\/\/medizinonline.com\/es\/nuevas-perspectivas-en-la-terapia-de-primera-linea\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/411839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=411839"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/411839\/revisions"}],"predecessor-version":[{"id":411842,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/411839\/revisions\/411842"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/411841"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=411839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=411839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=411839"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=411839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}